Erratum: (Arteriosclerosis, Thrombosis, and Vascular Biology (2013) 33 (2049-2050) DOI: 10.1161/ATVBAHA.113.301814);Genomic medicine for improved prediction and primordial prevention of cardiovascular disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 9, 2013, Pages 2049-2050

  Thanassoulis, George ^a   Peloso, Gina M ^b   O'Donnell, Christopher J ^b,c  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

atherosclerosis; cholesterol; genetics; genomics; myocardial infarction; prediction; prevention; risk

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; EDITORIAL; GENETIC ALGORITHM; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOMICS; HUMAN; LIFESTYLE MODIFICATION; MENDELIAN RANDOMIZATION ANALYSIS; PRECAMBRIAN; PREDICTION; PRIORITY JOURNAL;

EID: 84883308777     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/01.atv.0000434979.87020.eb     Document Type: Erratum

References (21)

1. O'Donnell CJ, Nabel EG. Genomics of cardiovascular disease. N Engl J Med. 2011;365:2098-2109.
2. Evans JP, Meslin EM, Marteau TM, Caulfield T. Genomics. Deflating the genomic bubble. Science. 2011;331:861-862.
3. Isaacs A, Willems SM, Bos D, Dehghan A, Hofman A, Ikram MA, Uitterlinden AG, Oostra BA, Franco OH, Witteman JC, van Duijn CM. Risk scores of common genetic variants for lipid levels influence atherosclerosis and incident coronary heart disease. Arterioscler Thromb Vasc Biol. 2013;33:2233-2239.
4. Thanassoulis G, O'Donnell CJ. Mendelian randomization: nature's randomized trial in the post-genome era. JAMA. 2009;301:2386-2388.
5. Thanassoulis G. Mendelian randomization: how genetics is pushing the boundaries of epidemiology to identify new causes of heart disease. Can J Cardiol. 2013;29:30-36.
6. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet. 2012;380:572-580.
7. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-1272.
8. Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, Kahn J, Afonso L, Williams KA Sr, Flack JM. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60:2631-2639.
9. Ganna A, Magnusson PKE, Pedersen NL, de Faire U, Reilly M, Ärnlöv J, Sundström J, Hamsten A, Ingelsson E. Multilocus genetic risk scores for coronary heart disease prediction. Arterioscler Thromb Vasc Biol. 2013;33:2267-2272.
10. Tikkanen E, Havulinna AS, Palotie A, Salomaa V, Ripatti S. Genetic risk prediction and a 2-stage risk screening strategy for coronary heart disease. Arterioscler Thromb Vasc Biol. 2013;33:2261-2266.
11. Hlatky MA, Greenland P, Arnett DK, et al; American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119:2408-2416.
12. Ripatti S, Tikkanen E, Orho-Melander M, et al. A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet. 2010;376:1393-1400.
13. Thanassoulis G, Peloso GM, Pencina MJ, Hoffmann U, Fox CS, Cupples LA, Levy D, D'Agostino RB, Hwang SJ, O'Donnell CJ. A genetic risk score is associated with incident cardiovascular disease and coronary artery calcium: the Framingham Heart Study. Circ Cardiovasc Genet. 2012;5:113-121.
14. Paynter NP, Chasman DI, Paré G, Buring JE, Cook NR, Miletich JP, Ridker PM. Association between a literature-based genetic risk score and cardiovascular events in women. JAMA. 2010;303:631-637.
15. Kaptoge S, Di Angelantonio E, Pennells L et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367:1310-1320
16. Chatterjee N, Wheeler B, Sampson J, Hartge P, Chanock SJ, Park JH. Projecting the performance of risk prediction based on polygenic analyses of genome-wide association studies. Nat Genet. 2013;45:400-5, 405e1.
17. Agewall S, DeGroot E, Marcos-Alberca P, Zamorano JL, Barrero AA, Badano LP, Perrone-Filardi P. Ultrasound and radiology surrogate endpoints in pharmacological studies. Atherosclerosis. 2012;224:12-24.
18. Razzouk L, Farkouh ME. Imaging outcomes in cardiovascular clinical trials. Nat Rev Cardiol. 2009;6:524-531.
19. Bloss CS, Schork NJ, Topol EJ. Effect of direct-to-consumer genomewide profiling to assess disease risk. N Engl J Med. 2011;364:524-534.
20. Knowles JW, Assimes TL, Kiernan M, Pavlovic A, Goldstein BA, Yank V, McConnell MV, Absher D, Bustamante C, Ashley EA, Ioannidis JP. Randomized trial of personal genomics for preventive cardiology: design and challenges. Circ Cardiovasc Genet. 2012;5:368-376.
21. Grant RW, O'Brien KE, Waxler JL, Vassy JL, Delahanty LM, Bissett LG, Green RC, Stember KG, Guiducci C, Park ER, Florez JC, Meigs JB. Personalized genetic risk counseling to motivate diabetes prevention: a randomized trial. Diabetes Care. 2013;36:13-19.